| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024762546 |
| P356 | DOI | 10.1186/S12879-016-1590-3 |
| P932 | PMC publication ID | 4919885 |
| P698 | PubMed publication ID | 27343082 |
| P2093 | author name string | Elie F Berbari | |
| Luke Mendez-Vigo | |||
| Elizabeth D Hermsen | |||
| Kenneth C Lamp | |||
| Minjung Yoon | |||
| Thomas Chung | |||
| P2860 | cites work | Daptomycin therapy for osteomyelitis: a retrospective study | Q34301398 |
| Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America | Q34316506 | ||
| Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. | Q34966777 | ||
| Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center | Q35926840 | ||
| Device-related infections: a review. | Q36283761 | ||
| Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty | Q36364029 | ||
| The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria | Q36381509 | ||
| Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry | Q36456328 | ||
| Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database | Q36929393 | ||
| Daptomycin: a review 4 years after first approval | Q36972980 | ||
| A current perspective on daptomycin for the clinical microbiologist | Q37263289 | ||
| High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. | Q37335865 | ||
| Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections | Q38003369 | ||
| High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. | Q42207374 | ||
| Cubicin Outcomes Registry and Experience (CORE) methodology | Q43923385 | ||
| Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry | Q43997965 | ||
| National Hospital Discharge Survey: 2007 summary | Q46693529 | ||
| Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study | Q46814162 | ||
| Clinical experience with daptomycin for the treatment of patients with osteomyelitis | Q46974836 | ||
| Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. | Q51190229 | ||
| Prosthetic Joint Infection | Q73235199 | ||
| Daptomycin | Q80608154 | ||
| High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study | Q84954829 | ||
| P921 | main subject | osteomyelitis | Q938983 |
| P304 | page(s) | 310 | |
| P577 | publication date | 2016-06-24 | |
| P1433 | published in | BMC Infectious Diseases | Q15759919 |
| P1476 | title | A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin | |
| P478 | volume | 16 |
| Q61589163 | Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in Static and Dynamic Models | cites work | P2860 |
Search more.